Vimarsana
Biggest News Aggregation in the World

Page 4 - Timothy Ko News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Timothy Ko. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Timothy Ko Today - Breaking & Trending Today

Ellis Martin Report: Entheon Biomedical's (CNSX:ENBI) HaluGen Psychedelics Genetic Test Ahead of Ethical Clinical DMT Therapy - Vimarsana News

Ellis Martin Report: Entheon Biomedical's (CNSX:ENBI) HaluGen Psychedelics Genetic Test Ahead of Ethical Clinical DMT Therapy

Join Ellis Martin for a conversation with Timothy Ko, the CEO of Entheon Biomedical (CNSX:ENBI) (OTCMKTS:ENTBF). Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule.

Entheon Biomedical Corp.: Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs - Vimarsana News

Entheon Biomedical Corp.: Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs

(2) Senior Pharmaceutical & Technology Executive and Current SVP, Chief Information Officer, North America at Kyowa Kirin International plc., Previously of IBM, Schering-Plough, Merck and Gilead Joins Entheon's Advisory Board Vancouver, British Columbia--(Newsfile Corp. - March 3, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (" Entheon" or the " Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce Nancy Maher as Special Advisor of Data Science and Regulatory Affairs, providing expertise on the ...

Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences - Vimarsana News

Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences

Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences Vancouver, British Columbia--(Newsfile Corp. - February 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (" Entheon" or the " Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides a production update on HaluGen Life Sciences Inc. (" HaluGen"), a wholly-owned subsidiary of Entheon, which is in the business of developing and commercializing a genetic test designed to identify specific DNA biomarkers in order to gauge the risk and potential of adverse re...

Ellis Martin Report: Entheon Biomedical (CNSX:ENBI) CEO Timothy Ko on the Ethical Clinical Use of DMT for Treating Substance Abuse, Depression, Anxiety and More - Vimarsana News

Ellis Martin Report: Entheon Biomedical (CNSX:ENBI) CEO Timothy Ko on the Ethical Clinical Use of DMT for Treating Substance Abuse, Depression, Anxiety and More

Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the 'untreatable case' and 'lost cause' from the norm to the exception.

Entheon Biomedical Corp.: Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development - Vimarsana News

Entheon Biomedical Corp.: Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development

Entheon Biomedical Corp.: Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development Entheon" or the " Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Dr. Brian Jahns to the role of Chief Business Officer. Dr. Jahns brings more than 20 years of business leadership and biopharmaceutical expertise to his role in overseeing the overall business development of Entheon, including the development and maintenance of strategic relationships with th...